Trending/NMO
Study shows drug reduces risk of relapse with neuromyelitis optica
ROCHESTER, Minn. — The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder…
October 8, 2012
Special Topics
Sign up
Social Media Network
A network for digital healthcare communicators
Mayo Clinic Connect
An online patient support community